Search - tctmd.com

Displaying 61 - 80 of 491

Sort: Relevancy | Date

Presentation TCT 2024

TCT 466: Renal Artery Denervation Combined With Pulmonary Vein Isolation in Patients With Heart Failure and Atrial Fibrillation: A Randomized Trial Preliminary Results and Study Design

Presenter: Tomasz Skowerski

October 28, 2024

Presentation TCT 2024

TCT 511: Peri-Coronary Adipose Tissue a Novel Marker for Post-Ablation Atrial Fibrillation Recurrence: A Comprehensive Systematic Review and Meta-Analysis Revealing Significant Association

Presenter: Sean Paknoosh

October 28, 2024

Presentation TCT 2024

TCT 540: Second-Generation Cryoballoon Ablation vs Contact-Force Sensing Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis

Presenter: Abdul Wali Khan

October 28, 2024

Presentation TCT 2024

TCT 544: Utility of C2HEST Score in Predicting Recurrence of Atrial Fibrillation After Catheter Ablation: A Systematic Review and Meta-Analysis With Reconstructed Time-to-Event Data

Presenter: Saman Al Barznji

October 28, 2024

Presentation TCT 2024

TCT 534: Outcomes of Stroke Prevention Strategies in Patients With Atrial Fibrillation and End-Stage Renal Disease

Presenter: Abdullah Al-Abcha

October 27, 2024

Presentation TCT 2024

TCT 183: Periprocedural Continuation Versus Interruption of Oral Anticoagulation During Transcatheter Aortic-Valve Implantation: Effect on Plasmatic Coagulation and Fibrinolysis

Presenter: Wilbert Bor

October 27, 2024

Presentation ESC 2024

The SHAM-PVI Study: A randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation

Presenter: Rick Veasey

September 02, 2024

Presentation ESC 2024

The efficacy of low-voltage-area ablation in patients with persistent atrial fibrillation: Results from a SUPPRESS-AF trial

Presenter: Masaharu Masuda

September 02, 2024

Presentation ESC 2024

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Presenter: Manesh R. Patel

September 01, 2024

Presentation ESC 2024

A Novel Model of Integrated Care of Older Patients With Atrial Fibrillation on Cardiovascular Outcomes in Rural China

Presenter: Minglong Chen

September 01, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Presentation ESC 2024

Stroke prevention & rhythm control Therapy: Evaluation of an Educational programme of the European society of cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation

Presenter: Dipak Kotecha

September 01, 2024

Presentation ESC 2024

Randomized invitation to systematic NT-proBNP and ECG screening in 75- year olds to detect atrial fibrillation – STROKESTOP II

Presenter: Katrin Kemp Gudmundsdottir

September 01, 2024

Presentation NY Valves 2024

Atrial Fibrillation and Left Atrial Appendage Closure (Occlusion): The Gap Between Prevalence and Penetrance

Presenter: Vivek Y. Reddy

June 07, 2024

Presentation THT 2024

IV Diltiazem Use in Patients with Atrial Fibrillation and Systolic Dysfunction

Presenter: Joseph Ibrahim

March 05, 2024

Presentation THT Abstracts 2024

IV Diltiazem Use in Patients with Atrial Fibrillation and Systolic Dysfunction

Presenter: Joseph Ibrahim

March 04, 2024

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

Presentation AHA 2023

AZALEA-TIMI 71

Presenter: Christian T. Ruff

November 15, 2023

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

Presentation TCT 2023

New Onset Atrial Fibrillation After PFO Closure: How to Manage?

Presenter: Harsimran Singh

October 26, 2023

Advertisement

TCT 466: Renal Artery Denervation Combined With Pulmonary Vein Isolation in Patients With Heart Failure and Atrial Fibrillation: A Randomized Trial Preliminary Results and Study Design

TCT 511: Peri-Coronary Adipose Tissue a Novel Marker for Post-Ablation Atrial Fibrillation Recurrence: A Comprehensive Systematic Review and Meta-Analysis Revealing Significant Association

TCT 540: Second-Generation Cryoballoon Ablation vs Contact-Force Sensing Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: An Updated Systematic Review and Meta-Analysis

TCT 544: Utility of C2HEST Score in Predicting Recurrence of Atrial Fibrillation After Catheter Ablation: A Systematic Review and Meta-Analysis With Reconstructed Time-to-Event Data

TCT 534: Outcomes of Stroke Prevention Strategies in Patients With Atrial Fibrillation and End-Stage Renal Disease

TCT 183: Periprocedural Continuation Versus Interruption of Oral Anticoagulation During Transcatheter Aortic-Valve Implantation: Effect on Plasmatic Coagulation and Fibrinolysis

The SHAM-PVI Study: A randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation

The efficacy of low-voltage-area ablation in patients with persistent atrial fibrillation: Results from a SUPPRESS-AF trial

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

A Novel Model of Integrated Care of Older Patients With Atrial Fibrillation on Cardiovascular Outcomes in Rural China

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Stroke prevention & rhythm control Therapy: Evaluation of an Educational programme of the European society of cardiology in a cluster-Randomised trial in patients with Atrial Fibrillation

Randomized invitation to systematic NT-proBNP and ECG screening in 75- year olds to detect atrial fibrillation – STROKESTOP II

Atrial Fibrillation and Left Atrial Appendage Closure (Occlusion): The Gap Between Prevalence and Penetrance

IV Diltiazem Use in Patients with Atrial Fibrillation and Systolic Dysfunction

IV Diltiazem Use in Patients with Atrial Fibrillation and Systolic Dysfunction

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

AZALEA-TIMI 71

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

New Onset Atrial Fibrillation After PFO Closure: How to Manage?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content